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Abstract
Background: Childhood obesity is associated with chronic low-grade inflammation considered as a precursor to
metabolic disease; however, the underlying mechanisms for this remain unclear. Studies in adults have implicated
gut derived gram-negative bacterial fragments known as lipopolysaccharide or endotoxin, activating the inflammatory
response, whilst the importance in childhood obesity is unclear. The aim of this research is to understand the
relationship between circulating endotoxin in childhood obesity, and its’ association with inflammatory and
cardiovascular (CV) injury biomarkers.
Methods: Fasted blood was obtained from children with varying degrees of obesity (age: 13.9 ± 2.3Yr; BMI:
35.1 ± 5.2 Kg/m2; n = 60). Multiplex CVD biomarker immunoassays were used to determine systemic levels of
inflammatory and vascular injury biomarkers, such as tumour necrosis factor-α (TNF-α), interleukin (IL-) 1β, 6, 8 and
10, plasminogen activator inhibitor-1 (PAI-1), soluble intercellular adhesion molecule type-1 (sICAM-1), matrix
metalloproteinase-9 (MMP-9), myeloperoxidase (MPO) and vascular endothelial growth factor (VEGF) as well as
endotoxin levels.
Results: Endotoxin levels demonstrated a significant and positive correlation with the markers for inflammation,
vascular injury and atherogenesis (TNF-α: r2 = 0.077, p < 0.05; PAI-1: r2 = 0.215, p < 0.01; sICAM-1: r2 = 0.159, p < 0.01;
MMP-9: r2 = 0.159, p < 0.01; MPO: r2 = 0.07, p < 0.05; VEGF: r2 = 0.161, p < 0.01). Males demonstrated significantly
higher circulating endotoxin than females (Males: 9.63 ± 5.34 EU/ml; p = 0.004; Females: 5.56 ± 4.06 EU/ml; n = 60)
in these BMI and age-matched cohorts.
Conclusion: The present study demonstrates for the first time a significant association between circulating
endotoxin and biomarkers of metabolic risk in children as young as 11 years. Thus, endotoxin-mediated sub-clinical
inflammation during childhood obesity may be a key contributor to T2DM and CVD development later in life.
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Background
Environmental, physical and nutritional factors appear
critical in determining lifetime disease risk profile for
cardiovascular disease (CVD), which is a leading cause
of mortality worldwide [1–3]. CVD development in later
life shows an increased risk when the condition is pre-
ceded by prior chronic inflammatory conditions [4–9].
Therefore the clinical value of determining the factors
that induce an inflammatory response in early life
appears important to address. Clearly childhood obesity
per se has a significant impact on disease risk, inflamma-
tion and CVD, however, adipose tissue (AT) may be an
early contributor to metabolic dysfunction through prior
systemic insults, which initiate an inflammatory re-
sponse [7, 8, 10–14].
One cellular mechanism for an increased inflamma-
tory response may arise through activation of the innate
immune system as observed in human AT [14, 15]. Pre-
vious studies have shown that increased activation of the
innate immune pathway may arise through excess circu-
lating gut derived bacteria, known as lipopolysaccharide
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(LPS) or endotoxin; which represents fragments from
the outer cell wall membrane of gram-negative bacteria
[14–16]. In human AT, it appears endotoxin has an im-
mediate impact on the innate immune pathway, acting
via key receptors known as the toll like receptors
(TLRs), which recognise antigens such as the LPS com-
ponent, to initiate an acute phase response to infection
[8, 14]. Stimulation of the TLRs leads to intracellular ac-
tivation of NFκB, a key transcription factor in the in-
flammatory cascade that regulates the transcription of
numerous pro-inflammatory adipocytokines [14, 15].
Therefore whilst in vitro, endotoxin may act as a medi-
ator of inflammation through activation of NFκB, lead-
ing to a rapid response, in an in vivo situation that may
be further exacerbated by an increasing fat mass, such as
in obesity [17–21].
Clinical studies have also implicated gut derived endo-
toxin as a direct ‘primary mediator’ to activate the in-
flammatory state, contributing to metabolic disease, with
current cross sectional data showing elevated systemic
endotoxin levels in conditions of obesity, coronary artery
disease, type 2 diabetes mellitus and fatty liver disease
[8, 14–16], which is reduced with weight change [17, 21].
Studies in adults has also shown circulating endotoxin to
be positively associated with waist, waist-hip-ratio, insulin
levels, inflammatory cytokines as well as lipids, including
total cholesterol, triglycerides, LDL-cholesterol and nega-
tively associated with HDL-cholesterol [8, 17–21]. Recent
studies in obese children and adolescents has demon-
strated that systemic inflammatory cytokines such as plas-
minogen activator inhibitor-1 (PAI-1) and C-reactive
protein (CRP) are elevated, along with vascular injury and
atherogenesis markers, such as vascular cell adhesion
molecule-1 (VCAM-1) and intercellular adhesion mol-
ecule type-1 (ICAM-1) [21–24]. Whether such pathogenic
biomarkers directly correlate with systemic endotoxin
concentrations in obese children and adolescents is
undetermined. We have examined and concluded
that bactrial endotoxin is a potential biomarker of




A total of 60 (unless stated otherwise in the figure le-
gend) obese children and adolescents with varying de-
grees of obesity (BMI: mean ± (SD) 35.1 ± 5.2 kg/m2; age:
13.9 ± 2.3 years) were recruited among those referred for
weight loss intervention to the obesity centre of the Isti-
tuto Auxologico Italiano. All subjects were above the
age and sex adjusted 97th BMI percentile, which defines
obesity according to the Italian BMI charts [25] and had
an age range of 8–18 years. The Ethics Committee of
the Italian Institute approved this study and informed
consent was obtained from all subjects and their parents.
All subjects underwent an oral glucose tolerance test
(1.75 g/Kg, up to a maximum of 75 g glucose in 250 ml
of water) following an overnight fast. Plasma samples
were drawn at baseline, after 30 min and 120 min, for
determination of plasma glucose and insulin concentra-
tion. Categorisation of glucose tolerance status was
made using the World Health Organisation criteria [20].
The impaired fasting glucose was defined by fasting glu-
cose levels ≥5.6 mmol/l [26]. Blood samples were drawn
for measurement of endotoxin, adiponectin and, markers
of inflammation and CVD. Blood pressure measure-
ments were taken as previously described [11]. Insulin
resistance was measured by HOMA-IR (fasting insulin x
fasting glucose/22.5) [27].
Biochemical measurements
Serum endotoxin was assayed using a Chromogenic
Limulus Amebocyte Lysate (LAL) test, which is a quantita-
tive test for gram-negative bacterial endotoxin (Cambrex,
New Jersey, USA) endotoxin-free vials were utilised
throughout. Gram-negative bacterial endotoxin catalyzes
the activation of a pro-enzyme in the Limulus Amebocyte
Lysate (LAL). The initial rate of activation is directly de-
termined by the concentration of endotoxin. The activated
enzyme catalyzes the splitting of p-nitroaniline (pNA)
from the colourless substrate Ac-lle-Glu-Ala-Arg-pNA.
The pNA released was measured photometrically at 405–
410 nm following termination of the reaction. The correl-
ation between the absorbance and the endotoxin concen-
tration is linear in the 0.1–1.0 EU/mL range. Intra-assay
CV 3 · 9 ± 0 · 46, inter-assay CV 9 · 6 ± 0 · 75. For the pur-
poses of these studies all samples were run in duplicate
within the same plate, therefore no inter-assay variability
was observed in this study. To assess recovery of endo-
toxin within the assay, previous studies have utilised
known concentrations of recombinant endotoxin (0.25
and 1.00 EU/mL) were added to diluted, pooled plasma to
determine whether the expected concentration correlated
closely with the actual observed value and whether there
were any variations due to reaction with plasma contents
[14]. Lyophilized endotoxin (E. coli origin) was used to
generate a standard curve with the Chromogenic LAL test
kit from Cambrex and produced a corresponding curve in
accordance with the manufacturer’s instructions. In
plasma, the recovery of spiked endotoxin was 82.0 ± 3.3 %
efficient, similar recovery data were noted for serum. Plate
to plate variability within the same experiment was 7.4 ±
0.9 %, these findings were similar to those observed from
assessment by Cambrex [14].
A multiplexed CVD Panel 1 immunoassay (Linco Re-
search, Missouri, USA) was utilised to examine the cir-
culating concentrations of the following inflammatory
and CVD risk biomarkers: TNF-α, PAI-1 (tPAI-1, total)
Varma et al. BMC Obesity  (2016) 3:3 Page 2 of 8
CRP, soluble intercellular adhesion molecule type-1
(sICAM-1), soluble vascular cell adhesion molecule-1
(sVCAM-1), MMP-9, MPO, VEGF and soluble endothe-
lial selectin (sE-Selectin). The CVD Panel 1 immuno-
assay had a sensitivity of 16–50,000 pg/ml for MMP-9,
MPO and PAI-1 and further, a sensitivity of 80–
250,000 pg/ml for sICAM-1, sVCAM-1 and sE-Selectin;
with an intra- and interassay CV of 4.5–12.3 % and 8.5–
16.3 %, respectively. Plasma glucose was measured using
an automated glucose analyser (Roche Diagnostics,
Mannheim, Germany). Serum insulin levels were mea-
sured by a chemiluminescent assay (DPC, Los Angeles,
USA) with a sensitivity of 14.3 pmol/l and intra- and
interassay CV of 3.7 and 6.7 %, respectively.
Statistical analysis
All analyses were performed using statistical software
(SPSS, version 14; Woking, UK). Variables that were not
normally distributed were log transformed. Differences
between groups were calculated using a Student’s t-test
for independent samples. A Pearsons’ correlation ana-
lysis was used to analyse bivariate relationships between
endotoxin and the various markers of inflammation and
vascular injury. Data were expressed as mean ± SD. A
p-value <0.05 was considered statistically significant.
Results
Effect of gender on biomarkers of inflammation
From this cohort, biochemical analysis was performed
on 24 male subjects and 36 female subjects with match-
ing BMI and age. Clinical and biochemical characteris-
tics of male and female obese subjects are provided in
Table 1. No significant gender differences were observed
in HOMA-IR, blood pressure or several markers of in-
flammation and CV injury.
Correlation of endotoxin with biomarkers of inflammation
and CVD in childhood & adolescent obesity
In this study circulating endotoxin concentrations sig-
nificantly and positively correlated with TNF-α (p < 0.05,
r2 = 0.077) and MCP-1 (p < 0.01, r2 = 0.178) (Fig. 1a, b).
However, no significant correlation was noted between
circulating endotoxin levels and CRP (p =N.S, r2 = −0.069).
With regards to CVD risk markers, circulating endo-
toxin concentrations further correlated with several
Table 1 Clinical and biochemical characteristics for obese, BMI
and age-matched male (n = 24) and female (n = 36) subjects
Clinical and biochemical
characteristics
Male Female p value
Subjects (±SD) Subjects (±SD)
Age (yrs) 14 ± 3 14 ± 2 -
BMI (kg/m2) 34.0 ± 5.1 35.6 ± 5.3 -
Fasting Glucose (mmol/l) 4.4 ± 0.3 4.5 ± 0.5 N/S
2 h glucose, mmol/l 6.0 ± 1.0 5.7 ± 1.0 N/S
HOMA-IR 2.6 ± 1.2 3.3 ± 2.1 N/S
Endotoxin (EU/ml) 10.1 ± 5.4 5.3 ± 3.7 p < 0.01**
CRP (μg/ml) 7.5 ± 8.3 9.0 ± 7.5 N/S
TNF-α (pg/ml) 5.0 ± 2.5 5.9 ± 5.8 N/S
PAI-1 (ng/ml) 27.0 ± 10.7 26.0 ± 15.7 N/S
sICAM-1 (ng/ml) 110.4 ± 37.4 103.1 ± 47.9 N/S
Systolic BP (mmHg) 121.0 ± 10.8 119.1 ± 8.5 N/S
Diastolic BP (mmHg) 74.0 ± 11.2 72.7 ± 8.5 N/S
Data are expressed as mean ± SD. significant differences in data between male
and female subjects are highlighted (P-Value **, p < 0.001)
A B
Fig. 1 Correlation between log endotoxin (EU/ml) levels and the inflammatory markers: (a) log TNF-α pg/ml (p < 0.05) (b) log MCP-1 ng/ml
(p < 0.01), in BMI and age-matched children and adolescents




Fig. 2 Correlation between log endotoxin (EU/ml) levels and the following markers of CVD: (a) log PAI-1 (ng/ml) (p < 0.05), (b) log sICAM-1 (ng/ml)
(p < 0.05), (c) log MMP-9 (pg/ml) (p < 0.05), (d) log MPO (pg/ml) (p < 0.05), (e) log VEGF (pg/ml) (p < 0.05) and (f) log eSelectin (X/ml) (p < 0.05) in BMI
and age-matched children and adolescents
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parameters of atherogenesis and vascular injury; these
included PAI-1 (p < 0.01, r2 = 0.215), sICAM-1 (p < 0.01,
r2 = 0.159), MMP-9 (p < 0.01, r2 = 0.159), MPO (p < 0.05,
r2 = 0.07) and VEGF (p < 0.01, r2 = 0.161) (Fig. 2a–f ). No
significant correlation was observed between endotoxin
and sE-Selectin levels (p = 0.055, r2 = 0.067) or sVCAM-1
levels (p = N.S, r2 = 0.054).
Additional analysis of serum concentration data revealed
that circulating endotoxin levels positively correlated with
systolic blood pressure (p < 0.05; r2 = 0.155; n = 37) (Fig. 3a)
and diastolic blood pressure (p < 0.05; r2 = 0.083; n = 51)
(Fig. 3b). Endotoxin was higher in males than females as a
direct comparison (Fig. 4).
Discussion
These current studies highlight that in childhood obesity
circulating endotoxin is significantly correlated with pro-
inflammatory markers, TNF-α, MCP-1, as well as bio-
markers of atherogenesis and vascular injury including
PAI-1, sICAM-1, MMP-9 and MPO, VEGF. Further-
more, data analysis also determined that circulating
endotoxin levels are positively correlated with both sys-
tolic and diastolic blood pressure in children with obes-
ity. Taken together these findings also indicate that the
presence of metabolic endotoxinaemia, which appears to
occur in childhood, correlates with pathogenic pro-
inflammatory factors in a similar manner to that noted
in adults with metabolic disease [14, 15, 17, 21, 22].
These studies also appear to suggest that the raised
endotoxin levels in childhood are coupled to a noted
high disease risk profile and blood pressure, which to-
gether ultimately could lead to an earlier life progression
of CVD. Endotoxin may also account for, in part, the
continual pro-inflammatory state experienced in obese
children [28–31].
These studies also observed for the first time a noted
significant rise in circulating endotoxin in boys com-
pared with girls. Whilst this was not the aim of the study
these findings appear consistent with gender-specific
effects noted in adults; maintained across several ethnic-
ities [19]. Prior studies in adults suggest a higher
endotoxin-induced pro-inflammatory cytokine release in
men than women, although this study in children did
not identify this gender specific aspect [32, 33]. Such a
disparity in endotoxin-induced pro-inflammatory cyto-
kine release between the children and adults with obes-
ity may arise, in part, due to the difference in exposure
time to endotoxin; which in obese adults may give rise
to long-term damaging inflammatory change leading to
T2DM [26, 34, 35].
These studies also suggest that changes in inflamma-
tion, vascular dysfunction, and blood pressure in child-
hood obesity may arise beyond the known impact of the
cardiometabolic lipid profile [29, 30, 32, 37, 38]. A key
mediator to increase disease risk arise from circulating
commensal bacterial endotoxin, derived from the gastro-
intestinal-tract eliciting a pro-inflammatory response in
prior childhood and adolescent obesity studies [36, 39,
40]. Additionally, adult studies highlight that diets high in
fat and or processed meat appear to raise endotoxin levels
further, whilst dairy products and other food combinations
may reduce endotoxin levels and inflammation [18, 41–
43]. As such further future insight into examining the im-
pact of diet on endotoxin levels in children with obesity
may highlight important interventions to reduce the long-
term health risk [14, 40, 44–46].
Several risk factors in childhood have been proposed
to predict the later development of CVD including obes-
ity, hypertension and endothelial dysfunction promoting
atherogenesis and thrombosis [47–50]. In our cohort of
A B
Fig. 3 Correlation between log endotoxin (EU/ml) levels and (a) systolic blood pressure (mm Hg) (n = 37) and (b) diastolic blood pressure (mm Hg)
(n = 51) in BMI and age-matched children and adolescents
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obese children and adolescents, several biomarkers of vas-
cular injury and endothelial dysfunction, including PAI-1,
sICAM-1, MMP-9, MPO and VEGF, were significantly
and positively correlated with circulating endotoxin con-
centrations. The observed pro-inflammatory biomarker
risk profile in the obese children appears to be similar to
both what has been identified in adults with CVD as well
as studies comparing obese and lean children [50, 51].
Hypertension has been identified as a key risk factor
for atherogenesis and vascular injury, and this study
noted a positive association between endotoxin with sys-
tolic and diastolic blood pressure. As such a diet that raises
endotoxin levels would appear to also increase blood pres-
sure. However this is a cross-sectional study, which there-
fore cannot determine a causal relationship, although
previous studies have demonstrated that mice fed a con-
tinuous endotoxin bolus, exhibited a subsequent increase
in vascular dysfunction [52, 53]. This is consistent with the
concept that an endotoxin-induced inflammatory response
in childhood obesity, may consequently contribute to an
accelerated risk of CVD in later life. Furthermore the noted
correlations between circulating endotoxin and biomarkers
of endothelial dysfunction, in this childhood obesity study,
could also promote a cluster of these pro-atherogenic fac-
tors contributing to accelerated atherosclerosis, arterial
stiffness and CVD in later life [37, 54–57].
This study had some limitations, namely: the cross-
sectional design which did not allow causal determinations
and a limited sample size indicating modest correlations.
Further, the lack of gender-effects on the correlations be-
tween endotoxin and the pro-inflammatory factors may
also be considered a reflection of the limited cohort size.
Thus, future studies exploring further aspects of these ob-
servations in larger cohorts are warranted.
Conclusion
In summary, this study highlights the relationship between
endotoxin and several inflammatory and CVD risk bio-
markers, particularly as an early player in obesity-related in-
flammatory disorders during childhood and adolescence.
Furthermore, even at an early age in the obese state, female
subjects exhibited lower endotoxin levels than their male
counterparts, suggesting a more favourable metabolic pro-
file. This may manifest in later life as delayed CVD mortal-
ity and morbidity for females in contrast to males. Finally,
among the inflammatory markers evaluated in this study,
endotoxin may serve as a potential mediator of sub-clinical
inflammation in childhood and adolescent obesity as noted
in adult studies.
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